Your browser doesn't support javascript.
loading
Recent successes in therapeutics for Ebola virus disease: no time for complacency.
Iversen, Patrick L; Kane, Christopher D; Zeng, Xiankun; Panchal, Rekha G; Warren, Travis K; Radoshitzky, Sheli R; Kuhn, Jens H; Mudhasani, Rajini R; Cooper, Christopher L; Shurtleff, Amy C; Nasar, Farooq; Sunay, Melek Me; Duplantier, Allen J; Eaton, Brett P; Zumbrun, Elizabeth E; Bixler, Sandra L; Martin, Shannon; Meinig, J Matthew; Chiang, Chih-Yuan; Sanchez-Lockhart, Mariano; Palacios, Gustavo F; Kugelman, Jeffrey R; Martins, Karen A; Pitt, Margaret L; Crozier, Ian; Saunders, David L.
Affiliation
  • Iversen PL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Kane CD; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Zeng X; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Panchal RG; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Warren TK; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Radoshitzky SR; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Kuhn JH; Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
  • Mudhasani RR; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Cooper CL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Shurtleff AC; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Nasar F; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Sunay MM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Duplantier AJ; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Eaton BP; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Zumbrun EE; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Bixler SL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Martin S; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Meinig JM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Chiang CY; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Sanchez-Lockhart M; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Palacios GF; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Kugelman JR; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Martins KA; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Pitt ML; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Crozier I; Integrated Research Facility at Fort Detrick, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Saunders DL; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA. Electronic address: david.l.saunders.mil@mail.mil.
Lancet Infect Dis ; 20(9): e231-e237, 2020 09.
Article in En | MEDLINE | ID: mdl-32563280
ABSTRACT
The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebola Vaccines / Antibodies, Monoclonal Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2020 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebola Vaccines / Antibodies, Monoclonal Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2020 Type: Article Affiliation country: United States